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Edited by Hans-Dieter KlenkAbstract The anti-viral type I interferon (IFN) response is
initiated by the immediate induction of IFNb, which is mainly
controlled by the IFN-regulatory factor-3 (IRF-3). The signaling
pathways mediating viral IRF-3 activation are only poorly
deﬁned. We show that the Rho GTPase Rac1 is activated upon
virus infection and controls IRF-3 phosphorylation and activity.
Inhibition of Rac1 leads to reduced IFNb promoter activity and
to enhanced virus production. As a downstream mediator of Rac
signaling towards IRF-3, we have identiﬁed the kinase p21-
activated kinase (PAK1). Furthermore, both Rac1 and PAK1
regulate the recently described IRF-3 activators, IjB kinase-e
and TANK-binding kinase-1, establishing a ﬁrst canonical virus-
induced IRF-3 activating pathway.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Interferon (IFN)b is one of the ﬁrst anti-viral cytokines
to be expressed upon virus infection, initiating an auto-
ampliﬁcation loop to cause an eﬃcient and strong type I
IFN response [1]. The IFNb enhanceosome, which medi-
ates the inducible expression of IFNb, carries binding sites
for transcription factors of three families, namely the AP-1
family members c-Jun and ATF-2, the NF-jB factors p50
and p65, and the interferon-regulatory factor (IRF-3) [2,3].
While AP-1 and NF-jB transcription factors are activated
by a variety of stimuli, a strong IRF-3 activation is se-
lectively induced upon virus infection, speciﬁcally by the
double-stranded RNA (dsRNA) that accumulates during
replication [4,5]. Thus, IRF-3 is a main determinant of a
strong virus- and dsRNA-induced IFNb response. Sur-
prisingly, there is only very limited information with re-
gard to the intracellular signaling chains that mediate
virus-induced IRF-3 activation, especially those which lead
to the virus speciﬁc C-terminal phosphorylation of the
factor [6]. So far, most attempts have failed to identify the
crucial mediators but rather helped to exclude a variety of
signaling components and pathways [7–9]. Only until re-
cently two non- canonical homologs of IjB kinases,
namely inhibitor of jB kinase epsilon (IKK-e), also known
as IKK-i [10], and TANK-binding kinase (TBK-1), also
known as NF-jB activating kinase (NAK) [11], have been
identiﬁed as virus-induced IRF-3 activators [12,13]. How-
ever, the signaling chain upstream of these kinases has not
been deﬁned yet. Using an IRF-3-binding promoter ele-
ment speciﬁcally responding to dsRNA or virus infections
in a screening approach, we have identiﬁed Rac1 as a
critical mediator of IRF-3 activation. This is a ﬁrst dem-
onstration that Rac1 is activated by a viral stimulus.
Furthermore, the observation that the Rac1 eﬀector p21-
activated kinase (PAK1) also plays a role in IRF-3 acti-
vation and both Rac1 and PAK1 are upstream of IKK-e
establish a ﬁrst virus-induced signaling cascade towards
IRF-3.blished by Elsevier B.V. All rights reserved.
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2.1. Viruses, cells and viral infections
Avian inﬂuenza virus A/Bratislava/79 (H7N7; fowl plague virus
(FPV)) and human inﬂuenza virus A/Puerto-Rico/8/34 (H1N1) (PR8)
were taken from the strain collection of the Institute of Virology in
Giessen, Germany, and were used for infection of diﬀerent cell lines.
Sendai virus strain ‘‘Z’’ was taken from the strain collection of the
Institute of Virology, Marburg, Germany, and has been passaged three
times in embryonated chicken eggs with high multiplicity. Madin–
Darby canine kidney (MDCK) cells or HEK293 cells were grown,
respectively, in MEM or DMEM, both containing 10% heat-inacti-
vated fetal bovine serum (FBS) and antibiotics. Human umbilical vein
endothelial cells (HUVEC) were obtained from Clonetics and cultured
as described [14]. The A549 lung epithelial cell line was grown in
Ham’s F12 supplemented with 10% FBS and antibiotics. Infections of
cells and titrations of progeny virus in the supernatants were essentially
performed as described [15]. A receptor-neutralizing monoclonal an-
tibody (mab) against the type I IFN receptor was purchased from PBL
Biomedical Laboratories.
The Myc-tagged expression plasmids, pRK5 Rac1wild-type (wt) and
pRK5 Rac1N17, as well as the empty expression vector, pRK5, were
provided by K.-D. Fischer, University of Ulm, Germany. Expression
plasmids for FLAG-tagged IKK-i/IKK-e wt and K38A mutant were
kindly provided by S. Akira, Department of Host Defense, Research
Institute for Microbial Diseases, Osaka University, Japan [10].
PCDNA3 FLAG-NAK/TBK-1 was a kind gift of Makato Nakanishi,
Department of Biochemistry, Nagoya City University Medical School,
Japan [11]. The plasmids pCMV PAK1 and pCMV PAK1 K299R
were a kind gift of I. Haase, Department of Dermatology and Center
for Molecular Medicine, University of Cologne (CMMC), Germany.
The 4 IRF3 construct contains four copies of the IRF3-binding
positive regulatory domain (PRD)I/III motif of the IFNb promoter in
front of a luciferase reporter gene. The IFNb promoter construct and
plasmids expressing dominant-negative IRF-35A or GFP-IRF-3 were
a kind gift of J. Hiscott, Lady Davis Institute for Medical Research,
McGill University, Montreal, Canada. A plasmid expressing HA-
tagged IRF-3 was kindly provided by S. Jennings, Institute of Virol-
ogy, Freiburg, Germany. MDCK and HEK293 cells were transfected
with Lipofectamine 2000 (Life Technologies) according to a protocol
by Basler et al. [16]. The dsRNA analog poly(IC) was purchased from
Sigma and was directly added to the cell supernatant for stimulation.
The speciﬁc Rho GTPase inhibitor toxin B of the Clostridium diﬃcile
strain VPI 10463 (TcdB-10463) was puriﬁed at the Institute of Medical
Microbiology, University of Mainz, Germany, and was used at the
indicated concentrations.
2.2. Rac1 activity assay
The Rac1-binding domain of PAK3 (aa 65–136) fused to GST
(plasmid kindly provided by Dr. Wolfgang Kranewitter, Salzburg,
Austria) was expressed in E. coli induced with 1 mM IPTG. The wa-
shed bacteria were run through the FrenchPress and supernatants were
cleared by centrifugation.
Host-cells were stimulated or infected for the indicated times, wa-
shed 2 with PBS and harvested in Lysis buﬀer (50 mM Tris, pH 7.4;
500 mM NaCl; 1% Triton X-100; 0.5% DOC; 0.1% SDS; 10 mM
MgCl2; and 10 lg/ml each of leupeptin, aprotinin and pefablock). 500
lg total cell lysate was mixed with 20 lg GST-RBD and rotated in the
presence of 25 ll washed glutathione–Sepharose beads for 45 min at
4 C. The beads were washed 3 with buﬀer (50 mM Tris, pH 7.4; 150
mM NaCl; 1% Triton X-100; 10 mM MgCl2; and 10 lg/ml each of
leupeptin, aprotinin and pefablock), sample buﬀer was added to the
beads and boiled. The protein samples were separated on an 12.5%
SDS–PAGE gel, proteins were blotted onto nitrocellulose membranes
and deteced by the anti-Rac1 antibody (clone 23A8; Biomol).
2.3. Luciferase assays, immunoprecipitations and Western blotting
For luciferase reporter gene assays cells were infected or stimulated
24 h after transfection and harvested at the indicated times in 150 ll of
lysis buﬀer (50 mM Na-MES, pH 7.8; 50 mM Tris–HCl, pH 7.8;
10 mM DTT and 2% Triton X-100). Luciferase activities were deter-
mined as described elsewhere [17] and are given as 2.5-fold activation
S.E.M. from three independent transfections.
For immunoprecipitations and Western blotting, cells were lysed in
Triton lysis buﬀer (TLB; 20 mM Tris–HCl, pH 7.4; 137 mM NaCl;10% glycerol; 1% Triton X-100; 2 mM EDTA; 50 mM sodium glyc-
erophosphate; 20 mM sodium pyrophosphate; 5 lg/ml aprotinin; 5 lg/
ml leupeptin; 1 mM sodium vanadate and 5 mM benzamidine) on ice
for 10–20 min. Cell lysates were cleared by centrifugation and were
either used for immunoprecipitation with the 12CA5 monoclonal anti-
HA antibody (puriﬁed at the MSZ, W€urzburg, Germany) and protein
A agarose (Roche) or directly subjected to SDS–PAGE and sub-
sequent blotting. Endogenous IRF-3 protein in crude lysates was de-
tected with an anti-rabbit IRF-3 anti-serum (Zytomed). HA-IRF-3,
GFP-IRF-3 or CREB-binding protein (CBP) were detected with the
12CA5 mab, an anti-GFP mab or an anti-CBP anti-serum (both from
Santa Cruz Biotechnology), respectively. Protein bands were visualized
in a standard enhanced chemiluminescence reaction (Amersham). In
some of the assays, loading controls were performed with an ERK2
anti-serum or diﬀerent Jun N-terminal kinase (JNK)1 anti-sera (Santa
Cruz Biotechnology).
2.4. Immunecomplex kinase assays
MDCK cells expressing FLAG-tagged forms of IKK-i/IKK-e or
NAK/TBK-1 were lysed in TLB and lysates were used for immuno-
precipitations using the anti-FLAG M2 mab (Sigma). Immunecom-
plexes were washed and then incubated with recombinant GST-IjBa
as a substrate in the presence of 100 lM unlabeled adenosine tri-
phosphate (ATP), 5 lCi [c32P]ATP and kinase buﬀer for 30 min at 30
C, essentially as previously described for IKK2 kinase assays [14].
Samples were then subjected to SDS–PAGE, blotted onto nitrocellu-
lose membranes and visualized by autoradiography. Western blot
analysis with the anti-FLAG antibody was performed to monitor
equal loading of kinases.3. Results
In order to screen for signaling mediators of IRF-3 activa-
tion, we have constructed a speciﬁc promoter reporter gene
plasmid carrying four copies of the IRF-3 responsive PRDI/III
region of the IFNb enhanceosome in front of a luciferase gene
(4 IRF-3). In the initial phase of a virus infection, this pro-
moter element has been demonstrated to speciﬁcally bind to
constitutively expressed IRF-3 as a dimer, while other induc-
ible factors, such as IRF-1 or IRF-7 are only bound during the
late ampliﬁcation phase [1]. Accordingly, the 4 IRF-3 pro-
moter is rapidly and speciﬁcally activated in response to
dsRNA stimulation or infection with a RNA virus, such as the
inﬂuenza A virus which is a known activator of IRF-3 [18]
(Fig. 1A). A signiﬁcant luciferase activity is already detected
2 h post-virus infection (data not shown) which greatly rules
out the involvement of inducible IRF-factors, such as IRF-1 or
IRF-7. Activation of the factor required productive virus
replication, since partially UV-inactivated inﬂuenza virus is
only poorly inducing transcriptional activity (Fig. 1B). The
same pattern of transcriptional activation is also observed with
an IFNb promoter/enhancer element, which is mainly con-
trolled by IRF-3 in response to virus infection (Fig. 1C). Other
signaling activators, such as TNF-a, IL-1b or TPA factors,
which readily activate NF-jB or AP-1-dependent transcription
failed to activate the 4 IRF-3 promoter (Fig. 1D). Finally,
the speciﬁcity of the construct to respond to IRF-3 in our
experimental setting was conﬁrmed by expression of a domi-
nant negative IRF-3 mutant (IRF-3 5A) which eﬃciently im-
paired virus-induced transcriptional activity (Fig. 1E). With
this speciﬁc tool, we screened for involvement of a variety of
signaling proteins in the cell by co-expressing corresponding
dominant-negative or constitutively active mutants. The screen
included several components of the ERK, JNK, p38 and
ERK5 mitogen-activated protein kinase (MAPK) signaling
cascades and components of the IKK/NF-jB module.
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Fig. 1. The 4 IRF-3 promoter element speciﬁcally responds to productive RNA-virus infection and dsRNA stimulation. MDCK cells (A–C,E) or
293 cells (D) were transfected with the empty TATA-luciferase vector (A, left side), with the 4 IRF-3 luciferase plasmid (A right, B,D,E) or with the
IFNb promoter luciferase plasmid (C). In (E), cells were cotransfected with empty vector or a plasmid expressing IRF-3 5A. After transfection, cells
were untreated (mock), infected with replication-competent (A,B,D,E) or with partially UV-inactivated inﬂuenza A virus (B,C) grown in embryo-
nated chicken eggs (MOI¼ 5), treated with the equal amount of egg ﬂuid from uninfected eggs (B,C), or with 50 lg/ml of the dsRNA analog poly(IC)
(dsRNA) (A), 10 ng/ml TNF-a (C), 500 U/ml IL1b 50 ng/ml IFNc or with 100 ng/ml TPA (C). After 4 h of infection or stimulation, cells were lysed
and assayed for luciferase activity. Data represent means S.E.M. of three independent transfections and are given as the ratio of luciferase activity
relative to the uninfected or unstimulated control.
232 C. Ehrhardt et al. / FEBS Letters 567 (2004) 230–238However, none of these mutants, that had been shown to ef-
ﬁciently act dominant-negatively or positively on their cellular
counterparts in other systems, showed any signiﬁcant eﬀect on
virus- or dsRNA-induced 4 IRF-3 promoter activity (data
not shown). These results were in line with and partly sup-
ported the negative data of earlier studies mainly performed
with more or less speciﬁc pharmacological inhibitors [7–9].
In the light of all these negative ﬁndings, it was quite sig-
niﬁcant that the activation of the 4 IRF-3 promoter element
was strongly aﬀected by the Rho GTPase family member
Rac1. Indeed, Rac1 was activated in response to virus infec-tions or dsRNA stimulation as determined in a GTPase pull-
down assay (Fig. 2A). Overexpression of wt Rac1 (Racwt)
results in enhanced virus-induced 4 IRF-3 promoter activity,
while expression of the dominant-negative mutant of Rac1
(RacN17) leads to a strong inhibition (Fig. 2B). The same ef-
fects of wt and mutant Rac1 were observed upon dsRNA
stimulation, suggesting that accumulation of viral RNA upon
productive virus replication is the main inducing component
(Fig. 2C). Rac1-dependent virus or dsRNA-induced promoter
activity is observed as early as 1–2 h post-infection (data not
shown) consistent with an early activation of Rac1 (Fig. 2A).
Fig. 2. Rac1 is activated and critical for virus and dsRNA-induced transcription from the 4 IRF-3 and the IFNb promoter. (A) 293 cells or A549
cells were infected with diﬀerent inﬂuenza A viruses (FPV or PR8, MOI¼ 10) or stimulated with dsRNA (100 lg/ml) for the times indicated. Cell
lysates were subjected to GST-Rac1BD pull-down assays that allow to selectively precipitate the active GTP loaded form of Rac1. Control blots were
performed in full cell lysates. (B–E) MDCK cells were transfected with the 4 IRF-3 (B,C) or IFNb (D,E) reporter gene plasmid and co-transfected
with empty vector, a Rac1 (Racwt) expression construct, or a plasmid expressing dominant-negative Rac1 (RacN17). Subsequently, cells were either
left unstimulated (mock), infected with inﬂuenza A virus (MOI¼ 5) for 4 h (B,D) or treated for 4 h with 50 lg/ml poly(IC) (dsRNA) (C, D). Lysates
were then prepared and assayed for luciferase activities.
C. Ehrhardt et al. / FEBS Letters 567 (2004) 230–238 233In accordance with the ﬁnding that early transcription from
the IFNb promoter/enhanceosome is mainly controlled by
IRF-3, the same results were obtained when using an IFNb
promoter reporter gene plasmid (Fig. 2D and E). Other Rho
GTPases such as wt and mutant RhoA showed a much weaker
eﬀect, while no inﬂuence was seen with wt or mutant Cdc42
(data not shown). This suggests a predominant Rac1 speciﬁc
function in IRF-3-dependent transcriptional activation.
IRF-3 is strongly phosphorylated at the C-terminus in re-
sponse to virus infection or dsRNA stimulation, and this
regulates its nuclear translocation and transactivation poten-
tial [2,4,19]. IRF-3 phosphorylation can be monitored by a
retardation of the protein in SDS–PAGE [6] and was detect-
able as early as 1–2 h after dsRNA stimulation or infection
with inﬂuenza A virus (Fig. 3A and B). If Rac1N17 was
transiently overexpressed in infected cells, the amounts of the
slower migrating form of IRF-3 protein are strongly reduced
(Fig. 3C).
Another way of speciﬁcally inhibiting the activity of Rac1
and other Rho GTPases, such as Cdc42 and RhoA, is treat-
ment with the C. diﬃcile toxin B. This leads to a reducedintrinsic GTPase activity and impaired membrane-cytosol cy-
cling due to chemical modiﬁcation [20,21]. In the presence of
the toxin TcdB-10463, virus- or dsRNA-induced IRF-3
phosphorylation was also eﬃciently blocked (Fig. 3D and E).
The eﬀect of the toxin most likely has to be attributed to its
action on Rac1, since in transfection assays dominant-negative
mutants of RhoA or Cdc42 showed no signiﬁcant activity
(data not shown).
Upon virus-induced phosphorylation IRF-3 forms dimers
that migrate to the nucleus [6]. Thus, dimerization is another
hallmark of IRF-3 activation. To analyze whether Rac aﬀects
IRF-3 dimerization, we performed co-immunoprecipitation
experiments with transfected IRF-3 fused to two diﬀerent
protein-tags. GFP-IRF-3 speciﬁcally immunoprecipitates with
HA-IRF-3 from lysates of infected cells (Fig. 3F), indicating
virus-induced dimerization. The dimerization is enhanced in
cells expressing Rac1wt but nearly abolished in Rac1N17
expressing cells (Fig. 3F).
After translocation to the nucleus, IRF-3 dimers bind to
transcriptional coactivators such as the CBP, which ﬁnally
results in a strong transcriptional activity of the IRF-3
Fig. 3. Virus- or dsRNA-induced IRF-3 phosphorylation, dimerization and association with CBP is regulated by Rac1. MDCK cells were infected
with either inﬂuenza A virus (MOI¼ 5) (A,C,D,F,G) or Sendai virus (MOI¼ 10) (H) or stimulated with 50 lg/ml poly(IC) dsRNA (B,E). Phos-
phorylated and unphosphorylated IRF-3 were detected by Western blotting as described in Section 2. (D,E) Cells were preincubated for 2 h with 10
ng/ml of the C. diﬃcile toxin B-10463 prior to infection with inﬂuenza A virus (MOI¼ 5) or stimulation with dsRNA (50 lg/ml) for 3 h. Proteins were
detected in lysates as described. (C,F,G,H) Cells were transfected with empty vector, Rac1wt or Rac1N17 24 h prior to infection with inﬂuenza A
virus for 3 h (C) or 4 h (D,F,G) (MOI¼ 5) or Sendai virus for 6 h (H) (MOI¼ 10). In some of the assays, cells were co-transfected with HA-tagged
IRF-3 alone (G,H) or in combination with a GFP-tagged IRF-3 (F). IRF-3, GFP-IRF-3 and CBP proteins were either directly detected in the crude
protein lysate (A–E) or upon co-immunoprecipitation with HA-IRF-3 (F–H). Equal protein loads were veriﬁed with JNK1-(A,B), ERK2- (C–E), or
an anti-HA-tag blots (F–H).
234 C. Ehrhardt et al. / FEBS Letters 567 (2004) 230–238harboring complex [6]. CBP association upon inﬂuenza virus
infection was also detected in HA-IRF-3 immunoprecipitates
and again was enhanced in Rac1wt expressing cells but abol-
ished in cells expressing Rac1N17 (Fig. 3G). Interestingly, the
same eﬀects of Rac1wt and mutant expression were observed if
cells were infected with Sendai virus (Fig. 3H), indicating that
Rac1 involvement may be a general phenomenon in RNA
virus-induced IRF-3 activation.
Since Rac1 is obviously not a kinase, the remaining task was
to identify the Rac eﬀector(s) that mediate the signal leading to
phosphorylation and transcriptional activity of IRF-3 in virus-
infected cells. Among the variety of Rac eﬀectors, the kinase
PAK1 has been previously demonstrated to be involved in
signaling leading to gene expression changes [22]. Thus, we
tested wt and various mutants of PAK1 in the IRF-3 pro-
moter–reporter gene assay. Although wt PAK1 did not inﬂu-
ence IRF-3 promoter activity, we observed a pronounced eﬀect
of dominant negative PAK1 (PAK K299R) (Fig. 4A). This
indicates that PAK1 activity is not suﬃcient yet required for
full virus-induced IRF-3 activation. Expression of dominant
negative PAK resulted in impaired dimerization (Fig. 4B and
C) and CBP association (Fig. 4D and E), both in inﬂuenza and
Sendai virus-infected cells. Thus, PAK1 is at least one of the
signaling components downstream of Rac1 that is involved in
RNA virus-induced IRF-3 activation.
Recently, two independent publications introduced two non-
canonical homologs of the IjB kinase family, namely IKK-eand TBK-1 as novel activators of IRF-3 [12,13]. Thus, the
question arose whether Rac1 and PAK1 are involved in the
pathway leading to viral IKK-e/TBK-1 and subsequent IRF-3
activation. IRF-3 promoter reporter gene assays revealed that
overexpression of Rac1 did not result in enhanced transcrip-
tional activity caused by expression of wt IKK-e in uninfected
cells, however, once cells were infected an additive eﬀect was
observed (Fig. 5A). This is in full accordance with the obser-
vations shown in Fig. 2 where Rac1wt overexpression only
results in enhanced IRF-3 activity in the presence of a viral or
dsRNA stimulus. Conversely, expression of dominant negative
Rac1 eﬃciently impaired IRF-3-mediated transcriptional ac-
tivation induced by IKK-e (Fig. 5A). Similar results were
obtained in parallel experiments using wt and dominant-neg-
ative PAK1 (Fig. 5B). This is an indication that Rac1 and
IKK-e act in an additive manner, however, it does not neces-
sarily mean that Rac1 is upstream of IKK-e. To address this
point, we expressed both FLAG-tagged versions of IKK-e and
TBK-1 in mock- and virus-infected cells and co-expressed wt
or dominant-negative forms of Rac1 or PAK1. Both kinases
were subsequently immunoprecipitated from cell lysates and
subjected to in vitro kinase assays to test for IKK-e and TBK-1
activity. Inﬂuenza virus infection resulted in a signiﬁcant ac-
tivation of IKK-e and TBK-1 in vector transfected cells
(Fig. 5C and D). Virus-induced activities of both kinases were
enhanced in cells overexpressing Rac1wt but strongly impaired
in cells expressing the dominant negative mutant of the
Fig. 4. Inhibition of PAK1 activity impairs virus-induced IRF-3 phosphorylation, dimerization, CBP association and transcriptional activity.
MDCK cells were transfected with empty vector, a wt PAK1 (PAK wt) expression construct, or a plasmid expressing dominant-negative PAK1
(PAK K299R). (A) Cells were co-transfected with the 4 IRF-3 reporter gene plasmid and subsequently left unstimulated (mock) or infected with
inﬂuenza A virus (MOI¼ 5) for 4 h followed by determination of luciferase activity in the cell lysates. (B–E) Cells were co-transfected with a plasmid
expressing HA-IRF-3 (D,E) or with two plasmids expressing either HA- or GFP-tagged IRF-3 (B,C). Cells were subsequently infected for 4 h with
PR8 (MOI¼ 5) (B,D) or for 6 h with Sendai virus (MOI¼ 10) (C,E). Cells were subjected to immunoprecipitation of HA-IRF-3 (B–E) and co-
immunoprecipitated GFP-IRF-3 (B,C) or CBP (D,E) was detected by Western blot. Equal protein loads of HA-IRF-3 in the immunoprecipitates
were veriﬁed by an anti-HA-tag Western blot.
C. Ehrhardt et al. / FEBS Letters 567 (2004) 230–238 235GTPase (Fig. 5C). Similar results were obtained in a parallel
assay expressing wt and dominant negative PAK1 (Fig. 5D).
This clearly indicates that both Rac1 and its eﬀector PAK1 are
upstream of IKK-e and TBK-1 during inﬂuenza virus-induced
activation of the kinases.
IRF-3 is a central mediator of anti-viral gene expression by
regulating type I IFNs and other anti-viral genes. If Rac1 is
involved in IRF-3 activation and the subsequent onset of the
IFN response, then inhibition of Rac1 in infected cells should
result in an enhanced virus production. This was indeed the
case, both in cells pre-treated with the inhibitor toxin TcdB-
10463 and in cells expressing dominant-negative Rac1
(Fig. 6A–D). We observed virus-titers of up to 2.5-fold the level
in controls, using two diﬀerent viruses and a variety of diﬀerent
cell types (Fig. 6A–D). Although the eﬀects are relatively weak
due to a strong counter-regulation of the IFN induction by
inﬂuenza virus, they are consistently observed in several cell
types and with diﬀerent virus isolates. Moreover, a similar de-
gree of enhanced virus replication is observed in infected cells
treated with an anti-type I IFN receptor blocking antibodies
(Fig. 6G) and in cells expressing a dominant-negative mutant of
the bona ﬁde IRF-3 activator IKK-e (Fig. 6F). Finally, as ex-
pected we observed a stronger eﬀect of Rac1wt and mutant on
Sendai virus replication (Fig. 6E). Thus, our results clearly
demonstrate that in cells with impaired Rho GTPase activity,
similar to cells expressing dominant-negative IKK-e, important
components of the innate anti-viral activity are missing.4. Discussion
Rho GTPases play a role in a variety of cellular responses
such as reorganization of the cytoskeleton, transcriptional
activation and apoptosis regulation [23,24]. Here, we have
discovered a novel function of the Rho GTPase Rac1 and its
eﬀector PAK1 in the innate immune response to virus infec-
tions. Rac1 represents the ﬁrst signaling GTPase shown to be
activated in response to virus infections and to be involved in
activation of IRF-3. Furthermore, we were able to track the
Rac-mediated signal to be transmitted via PAK1 to IKK-e and
TBK-1, which have been just recently identiﬁed as IRF-3
activating kinases [12,13].
The ﬁnding that overexpression of Rac1wt (Fig. 2) or an
active form of Rac (Rac1L61) (data not shown) did not sig-
niﬁcantly induce IRF-3 transcriptional activity on its own in-
dicates that Rac1 activity is required, yet not suﬃcient, to
induce IRF-3 activation. The same holds true for PAK1 in-
dicating that most likely more than one pathway targets IKK-e
and/or IRF-3 during virus infection. A variety of intracellular
signaling mediators have been tested by us and others for in-
volvement in virus-induced IRF-3 activation [7–9]. Among
these were also several Rac1 eﬀectors such as the IKK/NF-jB
pathway and the p38 and JNK MAPK pathway. Since dom-
inant-negative mutants or speciﬁc inhibitors of these Rac1
eﬀectors did not block IRF-3-dependent-promoter activation,
we can at least rule out their involvement. IRF-3 is
Fig. 5. Rac1 and PAK1 are upstream mediators of virus-induced IKK-e and TBK-1 activation. (A,B) MDCK cells were transfected with the 4 IRF-
3 reporter gene plasmid and cotransfected with empty vector or wt IKK-e. Cells were cotransfected with either wt or dominant negative Rac1 (A) or
PAK1 (B). 24 h later, cells were either left unstimulated (mock) or infected with inﬂuenza A virus (MOI¼ 5) for 4 h followed by determination of
luciferase activity in the cell lysates. (C,D) MDCK cells were transfected with constructs expressing either FLAG-IKK-e or FLAG-TBK-1 and
cotransfected with wt or dominant negative Rac1 (C) or PAK1 (D). 24 h post transfection cells were infected for 4 h and subsequently harvested.
Kinase activities of FLAG-IKK-e or FLAG-TBK-1 in the lysates were determined as described in Section 2. Equal loadings of FLAG-tagged kinases
in the assays were controlled by anti-FLAG Western blot.
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any apparent sequence consensus [2]. Thus, it is most likely
that more than one kinase mediates phosphorylation for full
viral activation of the factor. Recently, serine 369 of IRF-3 has
been identiﬁed as the minimal phosphoacceptor site required
for in vivo activation of IRF-3 in response to virus infection
and dsRNA stimulation [19]. Since the same site appears to be
targeted by IKK-e [12], and IKK-e is downstream of Rac1
(Fig. 6), it is most likely that the GTPase also acts via this site
following virus infection.
Another open question is the nature of the virus or dsRNA
sensor in infected cells, which appears to be located upstream
of Rac1. At least two dsRNA responsive signaling mediators
have been identiﬁed so far, the dsRNA-dependent protein ki-
nase (PKR) [25] and the toll-like receptor-3 (TLR3) [26]. While
a link between PKR and Rac1 is yet to be established, at least
for one member of the TLR family, TLR2, signaling via Rac1
was demonstrated [27]. Interestingly, in these studies TLR2-
Rac1 signaling targeted NF-jB activity directly on the p65
level via a pathway parallel to the IKK/IjB module [27]. This
supports a report that prominent Rac1 eﬀector functions may
well be independent of common eﬀectors such as MAPK
pathways or IKK/NF-jB [28]. Furthermore, Rac1 recruitment
to the TLR required tyrosine phosphorylation [27], while in
another study geldanamycin, an inhibitor of Src-family tyro-
sine kinases, was shown to aﬀect virus-induced IRF-3 activa-
tion. Finally, similar to our ﬁndings, downstream signalingfrom the TLR was blocked by dominant-negative Rac1 but
not by dominant negative-Cdc42 [7]. Taking these ﬁndings
together, it appears likely that TLR3 also signals via Rac1 in a
virus- or dsRNA-speciﬁc manner. It remains elusive whether
Rac1 acts downstream or parallel to the recently identiﬁed
adaptor proteins TICAM-1, TRIF and TRAM that have
been shown to mediate TLR3 generated signals into IFNb
production [29–31].
Another alternative mechanism of Rac1 involvement in viral
IRF-3 activation may work via endosomal sensing of viral
ssRNA through TLR7 [32–34], a process that would explain
the very early onset of the IRF-3 response upon virus
infection.
In a ﬁnal set of experiments, we have demonstrated that
inhibition of Rac1 indeed leads to enhanced virus production
to a same degree as observed with dominant negative IKK-e or
upon inhibition of type I IFN signaling in inﬂuenza virus-in-
fected cells. This fully supports our ﬁnding that Rac1 controls
activation of a transcription factor critical for the onset and
ampliﬁcation of the anti-viral IFN response. One might argue
that the eﬀects on replication are not too impressive. However,
it should be kept in mind that although inﬂuenza viruses ac-
tivate IRF-3 [18], these pathogens also express an eﬃcient IFN
antagonist, the viral NS1 protein, to keep the consequences of
IRF-3 activation and anti-viral gene expression limited [35]. In
this light, one would not expect much stronger diﬀerences.
Furthermore, the same eﬀects were also observed with Sendai
Fig. 6. Inhibition of Rac1 activity results in enhanced inﬂuenza A virus or Sendai virus propagation. MDCK cells (A), A549 (B) or HUVEC (C) were
treated with toxin B-10436 (10 ng/ml) before and during infection with diﬀerent inﬂuenza A viruses (MOI¼ 1). (D–F) Alternatively, MDCK cells
were transfected with vector or plasmids expressing Rac1wt (E), Rac1N17 (D,E) or dominant negative IKK-e (IKK-e K38A) (E) prior to infection
with inﬂuenza virus (MOI¼ 1) or Sendai virus (MOI¼ 0,1). (G) A549 cells were incubated with 20 lg/ml of a type I IFN receptor blocking antibody
and infected with diﬀerent inﬂuenza A viruses (MOI¼ 1). Supernatants were assayed for progeny virus yields 13 h (A–C), 8 h (D) or 24 h (E,G) post-
infection in standard plaque titrations. Virus yields of mock-treated cells were arbitrarily set as 100%.
C. Ehrhardt et al. / FEBS Letters 567 (2004) 230–238 237virus, suggesting that Rac1 involvement in the anti-viral re-
sponse may be a general phenomenon for RNA viruses.
In summary, we have identiﬁed a novel function for the Rho
GTPase Rac1 upstream of PAK1 and IKK-e/TBK-1 in the
innate immune response to virus infections targeting a major
determinant of virus-induced type 1 IFN expression, IRF-3.
Acknowledgements:We are very thankful to S. Akira, K.D. Fischer, I,.
Haase, J. Hiscott, S. Jennings and M. Nakanishi for providing plas-
mids. We also thank Martina Koch and Nicole Wittig for excellent
technical assistance and Andris Avots and Randy Cassada for critical
reading of the manuscript. The work was supported by grants Lu477/
4-5 and GRK 1045 of the Deutsche Forschungsgemeinschaft (DFG),
the Fonds der Chemischen Industrie (FdChI) and the Forschungs-
kommission der Medizinischen Fakult€at, University of D€usseldorf,
Germany.References
[1] Taniguchi, T. and Takaoka, A. (2002) Curr. Opin. Immunol. 14,
111–116.
[2] Hiscott, J., Pitha, P., Genin, P., Nguyen, H., Heylbroeck, C.,
Mamane, Y., Algarte, M. and Lin, R. (1999) J. Interferon.
Cytokine Res. 19, 1–13.
[3] Thanos, D. and Maniatis, T. (1995) Cell 83, 1091–1100.[4] Lin, R., Heylbroeck, C., Pitha, P.M. and Hiscott, J. (1998) Mol.
Cell. Biol. 18, 2986–2996.
[5] Yoneyama, M., Suhara, W., Fukuhara, Y., Fukuda, M., Nishida,
E. and Fujita, T. (1998) EMBO J. 17, 1087–1095.
[6] Servant, M.J., Grandvaux, N. and Hiscott, J. (2002) Biochem.
Pharmacol. 64, 985–992.
[7] Iwamura, T. et al. (2001) Genes. Cells 6, 375–388.
[8] Servant, M.J., ten Oever, B., LePage, C., Conti, L., Gessani, S.,
Julkunen, I., Lin, R. and Hiscott, J. (2001) J. Biol. Chem. 276,
355–363.
[9] Smith, E.J., Marie, I., Prakash, A., Garcia-Sastre, A. and Levy,
D.E. (2001) J. Biol. Chem. 276, 8951–8957.
[10] Shimada, T., Kawai, T., Takeda, K., Matsumoto, M., Inoue, J.,
Tatsumi, Y., Kanamaru, A. and Akira, S. (1999) Int. Immunol.
11, 1357–1362.
[11] Tojima, Y. et al. (2000) Nature 404, 778–782.
[12] Sharma, S., ten Oever, B.R., Grandvaux, N., Zhou, G.P., Lin, R.
and Hiscott, J. (2003) Science 300, 1148–1151.
[13] Fitzgerald, K.A. et al. (2003) Nat. Immunol. 4, 491–496.
[14] Goebeler, M., Gillitzer, R., Kilian, K., Utzel, K., Brocker, E.B.,
Rapp, U.R. and Ludwig, S. (2001) Blood 97, 46–55.
[15] Pleschka, S., Wolﬀ, T., Ehrhardt, C., Hobom, G., Planz, O.,
Rapp, U.R. and Ludwig, S. (2001) Nat. Cell Biol. 3, 301–305.
[16] Basler, C.F., Wang, X., Muhlberger, E., Volchkov, V., Paragas,
J., Klenk, H.D., Garcia-Sastre, A. and Palese, P. (2000) Proc.
Natl. Acad. Sci. USA 97, 12289–12294.
[17] Ludwig, S., Ehrhardt, C., Neumeier, E.R., Kracht, M., Rapp,
U.R. and Pleschka, S. (2001) J. Biol. Chem. 276, 10990–10998.
238 C. Ehrhardt et al. / FEBS Letters 567 (2004) 230–238[18] Kim, M.J., Latham, A.G. and Krug, R.M. (2002) Proc. Natl.
Acad. Sci. USA 99, 10096–10101.
[19] Servant, M.J., Grandvaux, N., ten Oever, B.R., Duguay, D., Lin,
R. and Hiscott, J. (2003) J. Biol. Chem. 278, 9441–9447.
[20] Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M.
and Aktories, K. (1995) Nature 375, 500–503.
[21] Genth, H., Aktories, K. and Just, I. (1999) J. Biol. Chem. 274,
29050–29056.
[22] Aspenstrom, P. (1999) Curr. Opin. Cell Biol. 11, 95–102.
[23] Bar-Sagi, D. and Hall, A. (2000) Cell 13, 227–238.
[24] Van Aelst, L. and D’Souza-Schorey, C. (1997) Genes Dev. 11,
2295–2322.
[25] Williams, B.R. (1999) Oncogene 18, 6112–6120.
[26] Alexopoulou, L., Holt, A.C., Medzhitov, R. and Flavell, R.A.
(2001) Nature 413, 732–738.[27] Arbibe, L. et al. (2000) Nat. Immunol. 1, 533–540.
[28] Murga, C., Zohar, M., Teramoto, H. and Gutkind, J.S. (2002)
0ncogene 21, 207–216.
[29] Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. and
Seya, T. (2003) Nat. Immunol. 4, 161–167.
[30] Yamamoto, M. et al. (2003) Nat. Immunol. 4, 1144–1150.
[31] Fitzgerald, K.A. et al. (2003) J. Exp. Med. 198, 1043–1055.
[32] Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S. and Reis, E.S.C.
(2004) Science 303, 1529–1531.
[33] Heil, F. et al. (2004) Science 303, 1526–1529.
[34] Lund, J.M., Alexopoulou, L., Sato, A., Karow, M., Adams, N.C.,
Gale, N.W., Iwasaki, A. and Flavell, R.A. (2004) Proc. Natl.
Acad. Sci. USA.
[35] Talon, J., Horvath, C.M., Polley, R., Basler, C.F., Muster, T.,
Palese, P. and Garcia-Sastre, A. (2000) J. Virol. 74, 7989–7996.
